Companies · Other Health Care

Venus Concept Inc.

TORONTO · Other Health Care

Diligence memoA one-page analyst read on Venus Concept Inc. — recommendation, valuation, rhythm, risks.
$194.2M
Total raised · real
11
Rounds
0.5×
Latest step-up
Top 3%
Sector rank · raised
Series C
Latest stage · inferred · Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Venus Concept Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.01× the median modeled value of Series C Other Health Care companies in 2022–2024 (47 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Venus Concept Inc. is one of 5376 Other Health Care companies tracked from TORONTO. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2024-02-27
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeed · 2011-06-01 Raised $2.0M (real) Modeled valuation $50M (est)Seed2011Series C · 2011-08-02 Raised $41M (real) Modeled valuation $937M (est)Series C2011Series C · 2013-11-08 Raised $45M (real) Modeled valuation $1.0B (est)Series C2013Series C · 2015-05-29 Raised $4.8M (real) Modeled valuation $110M (est)Series C2015Series C · 2016-08-31 Raised $24M (real) Modeled valuation $546M (est)Series C2016Series C · 2019-11-07 Raised $51M (real) Modeled valuation $1.2B (est)Series C2019Series C · 2021-12-15 Raised $4.7M (real) Modeled valuation $74M (est)Series C2021Series C · 2021-12-15 Raised $12M (real) Modeled valuation $193M (est)Series C2021Series C · 2022-11-18 Raised $6.7M (real) Modeled valuation $83M (est)Series C2022Series C · 2023-05-15 Raised $2.0M (real) Modeled valuation $22M (est)Series C2023Series C · 2024-02-27 Raised $1.1M (real) Modeled valuation $9.8M (est)Series C2024Cumulative $194M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.0M · 2011
Series C$41.0M · 2011no Series A / Series B on file
Series C extension$45.2M · 2013
Series C extension$4.8M · 2015
Series C extension$23.9M · 2016
Series C extension$50.5M · 2019
Series C extension$4.7M · 2021
Series C extension$12.3M · 2021
Series C extension$6.7M · 2022
Series C extension$2.0M · 2023
Series C extension$1.1M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$9.8M
Base estimate est.
$4.0M
Conservative case
$15.6M
Upside case
$7.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $49.6M · 2011-06-012011Series C · modeled $937.4M · 2011-08-02Series C · modeled $1.0B · 2013-11-08Series C · modeled $110.2M · 2015-05-29Series C · modeled $546.1M · 2016-08-31Series C · modeled $1.2B · 2019-11-07Series C · modeled $74.5M · 2021-12-15Series C · modeled $192.7M · 2021-12-15Series C · modeled $83.2M · 2022-11-18Series C · modeled $21.9M · 2023-05-15Series C · modeled $9.8M · 2024-02-272024
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
2.3 yr
Elapsed time used
2.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
15 mo
Avg between rounds
$15.2M/yr
Capital velocity
15.1 yr
On record since
2011
First round
11
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 80× above median
This company$194.2M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.0× of median
This company$1.1M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 0.4× of median
This company$9.8M
Sector median$22.1M

Raised more than 98% of sector peers (real $). Modeled value above 34% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #46 of 47.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Gravie, Inc. · Series C Raised $160.7M · modeled $1.3B (est)EmpowerMe Holdings, LLC · Series C Raised $96.6M · modeled $1.3B (est)Color Holdings, L.P. · Series C Raised $90.9M · modeled $1.1B (est)RSR Senior Residences, LLC · Series C Raised $73.7M · modeled $1.1B (est)Gynesonics, Inc · Series C Raised $299.1M · modeled $1.0B (est)Hello Heart Inc. · Series C Raised $127.0M · modeled $1.0B (est)Beta Bionics, Inc · Series C Raised $277.5M · modeled $1.0B (est)BioDerm Holdings, LP · Series C Raised $130.9M · modeled $1.0B (est)Kindbody, Inc. · Series C Raised $95.6M · modeled $874.4M (est)Drconsulta Ltd. · Series C Raised $140.1M · modeled $836.7M (est)Fountain Life, LLC · Series C Raised $103.9M · modeled $827.7M (est)TherapyMatch, Inc. · Series C Raised $100.0M · modeled $808.6M (est)Venus Concept Inc. (this company) Raised $194.2M · modeled $9.8M (est)Venus Concept Inc.
CompanyStageRaised · realValue · estvs peer med.
Gravie, Inc.Series C$160.7M$1.3B2.04×
EmpowerMe Holdings, LLCSeries C$96.6M$1.3B1.92×
Color Holdings, L.P.Series C$90.9M$1.1B1.75×
RSR Senior Residences, LLCSeries C$73.7M$1.1B1.71×
Gynesonics, IncSeries C$299.1M$1.0B1.58×
Hello Heart Inc.Series C$127.0M$1.0B1.54×
Beta Bionics, IncSeries C$277.5M$1.0B1.54×
BioDerm Holdings, LPSeries C$130.9M$1.0B1.53×
Kindbody, Inc.Series C$95.6M$874.4M1.33×
Drconsulta Ltd.Series C$140.1M$836.7M1.28×
Fountain Life, LLCSeries C$103.9M$827.7M1.26×
TherapyMatch, Inc.Series C$100.0M$808.6M1.23×
Venus Concept Inc. this companySeries C$194.2M$9.8M0.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.0M2011-06-01$10.0M$49.6M85%
Series C$41.0M2011-08-02$273.3M$937.4M85%
Series C$45.2M2013-11-08$301.4M$1.0B85%
Series C$4.8M2015-05-29$32.1M$110.2M85%
Series C$23.9M2016-08-31$159.2M$546.1M90%
Series C$50.5M2019-11-07$336.8M$1.2B90%
Series C$4.7M2021-12-15$31.6M$74.5M90%
Series C$12.3M2021-12-15$81.7M$192.7M90%
Series C$6.7M2022-11-18$44.8M$83.2M90%
Series C$2.0M2023-05-15$13.3M$21.9M90%
Series C$1.1M2024-02-27$7.3M$9.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.0M2011-06-01
    • First recorded raise — entered as Seed.
    • 26 investors on this round.
  2. Series C$41.0M2011-08-02
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 20.5× larger than the prior — scaling up.
    • 35 investors on this round.
  3. Series C$45.2M2013-11-08
    • Raised again after 27 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(b) (was Rule 06).
    • 396 investors on this round.
  4. Series C$4.8M2015-05-29
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 9.4× smaller than the prior — bridge or down round.
    • 34 investors on this round.
  5. Series C$23.9M2016-08-31
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 5.0× larger than the prior — scaling up.
    • 152 investors on this round.
  6. Series C$50.5M2019-11-07
    • Raised again after 38 mo — slower than the ~14 mo sector norm.
    • Round 2.1× larger than the prior — scaling up.
    • 28 investors on this round.
  7. Series C$4.7M2021-12-15
    • Raised again after 25 mo — slower than the ~14 mo sector norm.
    • Round 10.7× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  8. Series C$12.3M2021-12-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.6× larger than the prior — scaling up.
    • 9 investors on this round.
  9. Series C$6.7M2022-11-18
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  10. Series C$2.0M2023-05-15
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 3.4× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  11. Series C$1.1M2024-02-27
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 2 investors on this round.
Intelligence
2025 ~Q2
Modeled next raise · ~15mo cadence
$1.1M
Modeled next size est.range $1.1M$1.8M
0.5×
Last step-up
$15.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Garheng Kong15 other2019-11
Craig Taylor12 other2016-08
Frederic Moll9 other2019-11
FRED MOLL7 other2011-06
JEFF BIRD6 other2011-06
William Kelley5 other2019-11
Juliet Tammenoms Bakker4 other2019-11
Anthony Natale3 other2019-11
DOUG KELLY3 other2011-06
Emmett Cunningham3 other2016-08
Scott Barry3 other2019-11
Brent Nixon2 other2016-08
Domenic Serafino2 other2019-11
Gil Kliman2 other2013-11
James McCollum2 other2015-05
Shelley Thunen2 other2015-05
TOM FOGARTY2 other2011-06
Anna Georgiadis1 other2019-11
Domenic Della Penna1 other2019-11
Domenic Di Sisto1 other2019-11
Emmett Cunningham, Jr.1 other2013-11
Fritz LaPorte1 other2019-11
GIL KILMAN1 other2011-06
JIM MCCOLLUM1 other2011-06
Registry & provenance

Venus Concept Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1409269
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Venus Concept Ltd.Other Health CareSeries B$66.5M$311.3Mnetwork12 shared operators · same sector
MIVI Neuroscience, Inc.Other Health CareSeries C$67.4M$4.3Mnetwork3 shared operators · same sector · same stage
Avedro IncOther Health CareSeries C$158.4M$571.6Mnetwork1 shared operator · same sector · same stage
PROCEPT BioRobotics CorpOther Health CareSeries D+$348.8M$1.6Bnetwork2 shared operators · same sector
Avail Medsystems, Inc.Other Health CareSeries C$126.7M$2.2Bnetwork1 shared operator · same sector · same stage
Spirox, Inc.Other Health CareSeries C$98.2M$1.0Bnetwork1 shared operator · same sector · same stage
RxSight, Inc.Other Health CareSeries C$76.4M$1.1Bnetwork1 shared operator · same sector · same stage
Ceribell, Inc.Other Health CareSeries C$52.5M$975.2Mnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Venus Concept Ltd.Other Health CareSeries B$311.3M98%
Venus Health Science, LLCHealthtechSeed$6.3M89%
MARS Bioimaging LtdOther Health CareSeed$49.6M84%
BioMatrix Holdings, L.L.C.Other Health CareSeries C$1.8B83%
Project Belle LLCOther Health CareSeries A$7.4M83%
Ps-Fertility, Inc.Other Health CareSeed$11.0M83%
Prixz, Inc.Other Health CareSeries A$97.3M83%
SciLogica CorpOther Health CareSeries A$9.7M82%
Frequently asked
How much funding has Venus Concept Inc. raised?
Venus Concept Inc. has raised approximately $194.2M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is Venus Concept Inc.'s estimated valuation?
Provath's modeled valuation for Venus Concept Inc. is approximately $9.8M (modeled range $4.0M–$15.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Venus Concept Inc. at?
Venus Concept Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Feb 27.
What does Venus Concept Inc. do and where is it based?
Venus Concept Inc. operates in the Other Health Care sector, based in TORONTO.
Explore related

See where Venus Concept Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Venus Concept Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.